Author:
Trimble Edward L.,Christian Michaele C.
Subject
Obstetrics and Gynaecology,Oncology
Reference8 articles.
1. Walker JL, Armstrong D, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase II trial of intravenous versus intraperitoneal chemotherpy in optimal stage II ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol (in press).
2. Armstrong DK, Bundy B, Wenzel L, et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian carncer: a Gynecologic Oncology Group study. New Engl J Med (in press).
3. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer;Alberts;N. Engl. J. Med.,1996
4. Phase III trial of standard‐dose intravenous cisplatin plus paclitaxel versus moderately high‐dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small‐volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group;Markman;J. Clin. Oncol.,2001
5. Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy;Piccart;Int. J. Gynecol. Cancer,2003
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献